Wealth Enhancement Advisory Services LLC Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wealth Enhancement Advisory Services LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 34.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,259 shares of the medical research company's stock after purchasing an additional 3,398 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in IQVIA were worth $2,338,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. American National Bank & Trust purchased a new position in IQVIA during the first quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in IQVIA during the fourth quarter valued at approximately $39,000. Lee Danner & Bass Inc. purchased a new position in IQVIA during the fourth quarter valued at approximately $44,000. Finally, Zions Bancorporation N.A. raised its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on IQV shares. Barclays reduced their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. UBS Group cut their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Mizuho cut their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Price Performance

IQVIA stock opened at $157.53 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The stock has a market cap of $27.25 billion, a P/E ratio of 21.46, a PEG ratio of 1.75 and a beta of 1.28. The company has a 50-day moving average price of $149.26 and a 200 day moving average price of $174.35. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same period last year, the business earned $2.54 earnings per share. IQVIA's revenue was up 2.5% compared to the same quarter last year. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.